Cite
HARVARD Citation
Barber, B. et al. (2022). Safety, pharmacokinetics, and antimalarial activity of the novel triaminopyrimidine ZY-19489: a first-in-human, randomised, placebo-controlled, double-blind, single ascending dose study, pilot food-effect study, and volunteer infection study. Lancet infectious diseases. 22 (6), pp. 879-890. [Online].